Gastroenterological Perspectives on Acute Cardiac Care — the Management of Patients with Implanted Coronary Stents Following an Acute Coronary Syndrome

1. Bhuiya FA, Pitts SR, McCaig LF. Emergency department visits for chest pain and abdominal pain: United States, 1999–2008. NCHS Data Brief. 2010;43:1-8.Search in Google Scholar

2. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17:110-123. doi: 10.5056/jnm.2011.17.2.110.10.5056/jnm.2011.17.2.110Open DOISearch in Google Scholar

3. Bhatt DL, Scheiman J, Abraham NS, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894-1909. doi: 10.1161/CIRCULATIONAHA.108.191087.10.1161/CIRCULATIONAHA.108.191087Open DOISearch in Google Scholar

4. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol. 2000;30:S39-S41.Search in Google Scholar

5. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology. 2016;150:1368-1379. doi: 10.1053/j.gastro.2016.02.012.10.1053/j.gastro.2016.02.012Open DOISearch in Google Scholar

6. Herregods TVK, Bredenoord AJ, Oors JM, Bogte A, Smout AJPM. Determinants of the Association between Non-Cardiac Chest Pain and Reflux. Am J Gastroenterol. 2017;112:1671-1677. doi: 10.1038/ajg.2017.288.10.1038/ajg.2017.288Open DOISearch in Google Scholar

7. Faybush EM, Fass R. Gastroesophageal reflux disease in noncardiac chest pain. Gastroenterol Clin North Am. 2004;33:41-54.10.1016/S0889-8553(03)00131-6Search in Google Scholar

8. Roman C, Bruley des Varannes S, Muresan L, Picos A, Dumitrascu DL. Atrial fibrillation in patients with gastrointestinal reflux disease: a comprehensive review. World J Gastroenterol. 2014; 20:9592-9599. doi: 10.3748/wjg.v20.i28.9592.10.3748/wjg.v20.i28.9592411059425071357Search in Google Scholar

9. Anderson JL, Adams CD, Antman EM, et al. American Heart Association Task Force on Practice Guidelines; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007;116:e.148e304. doi: 10.1016/j.jacc.2007.02.01310.1016/j.jacc.2007.02.01317692738Open DOISearch in Google Scholar

10. Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205e41. doi: 10.1016/j.jacc.2009.10.015.10.1016/j.jacc.2009.10.01519942100Search in Google Scholar

11. Egholm G, Thim T, Madsen M, et al. Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. Endosc Int Open. 2016;4:E527-E533. doi: 10.1055/s-0042-102649.10.1055/s-0042-102649487480127227109Open DOISearch in Google Scholar

12. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32:2922-2932. doi: 10.1093/eurheartj/ehr373.10.1093/eurheartj/ehr37322019823Open DOISearch in Google Scholar

13. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018;53:34-78. doi: 10.1093/ejcts/ezx334.10.1093/ejcts/ezx334Open DOISearch in Google Scholar

14. Zeymer U, Hohlfeld T, Vom Dahl J, et al. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thromb Haemost. 2017;117:625-635. doi: 10.1160/TH16-08-0650.10.1160/TH16-08-0650Open DOISearch in Google Scholar

15. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.10.1056/NEJMoa0904327Open DOISearch in Google Scholar

16. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. doi: 10.1056/NEJMoa050522.10.1056/NEJMoa050522Open DOISearch in Google Scholar

17. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621. doi: 10.1016/S0140-6736(05)67660-X.10.1016/S0140-6736(05)67660-XOpen DOISearch in Google Scholar

18. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974. doi: 10.1016/S0140-6736(09)61751-7.10.1016/S0140-6736(09)61751-7Open DOISearch in Google Scholar

19. Negovan A, Iancu M, Moldovan V, et al. The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy. Eur J Intern Med. 2017;44:62-66. doi: 10.1016/j.ejim.2017.05.017.10.1016/j.ejim.2017.05.01728576397Open DOISearch in Google Scholar

20. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708-1713, 1713a-1713b. doi: 10.1093/eurheartj/eht042.10.1093/eurheartj/eht04223425521Open DOISearch in Google Scholar

21. Negovan A, Iancu M, Moldovan V, et al. Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterol Res Pract. 2016;2016:7230626. doi: 10.1155/2016/7230626.10.1155/2016/7230626499278927579036Open DOISearch in Google Scholar

22. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917. doi: 10.1056/NEJMoa1007964.10.1056/NEJMoa100796420925534Open DOISearch in Google Scholar

23. Gargiulo G, Costa F, Ariotti S, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J. 2016;174:95-102. doi: 10.1016/j.ahj.2016.01.015.10.1016/j.ahj.2016.01.01526995375Open DOISearch in Google Scholar

24. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-719.10.1160/TH08-12-0808Search in Google Scholar

25. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260. doi: 10.1016/j.jacc.2007.06.064.10.1016/j.jacc.2007.06.06418206732Open DOISearch in Google Scholar

26. Simon N, Finzi J, Cayla G, et al. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokineticpharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71:1059-1066. doi: 10.1007/s00228-015-1882-3.10.1007/s00228-015-1882-326071277Open DOISearch in Google Scholar

27. Negovan A, Voidăzan S, Pantea M, et al. The AGT A-20 C gene polymorphism is associated with ulcer in Romanian patients treated with low-dose aspirin. Rev Romana Med Lab. 2015;23:179-187. doi: https://doi.org/10.1515/rrlm-2015-0017.10.1515/rrlm-2015-0017Open DOISearch in Google Scholar

28. Furtado RH, Giugliano RP, Strunz CM, et al. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. Am J Cardiovasc Drugs. 2016;16:275-284. doi: 10.1007/s40256-016-0172-5.10.1007/s40256-016-0172-527289472Open DOISearch in Google Scholar

29. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015;10:e0124653. doi: 10.1371/journal.pone.0124653.10.1371/journal.pone.0124653446257826061035Search in Google Scholar

30. Sherwood MW, Melloni C, Jones WS, et al. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc. 2015;4: e002245. doi: 10.1161/JAHA.115.002245.10.1161/JAHA.115.002245484522726514161Open DOISearch in Google Scholar

31. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol. 2010;26:611-617. doi: 10.1097/MOG.0b013e32833e91eb.10.1097/MOG.0b013e32833e91eb20948372Open DOISearch in Google Scholar

32. Berger PB, Bhatt DL, Fuster V, et al. CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121:2575-2583. doi: 10.1161/CIRCULATIONAHA.109.895342.10.1161/CIRCULATIONAHA.109.89534220516378Open DOISearch in Google Scholar

33. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26:125-140. doi: 10.1016/j.bpg.2012.01.011.10.1016/j.bpg.2012.01.01122542151Open DOISearch in Google Scholar

34. Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111:705-710. doi: 10.1016/j.jfma.2011.11.028.10.1016/j.jfma.2011.11.02823265750Open DOISearch in Google Scholar

35. Sengupta N, Tapper EB, Patwardhan VR, et al. Risk Factors for Adverse Outcomes in Patients Hospitalized With Lower Gastrointestinal Bleeding. Mayo Clin Proc. 2015;90:1021-1029. doi: 10.1016/j.mayocp.2015.04.024.10.1016/j.mayocp.2015.04.024477025626141075Open DOISearch in Google Scholar

36. Aoki T, Nagata N, Niikura R, et al. Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2015;13:488-494. doi: 10.1016/j.cgh.2014.06.023.10.1016/j.cgh.2014.06.02324997327Open DOISearch in Google Scholar

37. Shaukat A, Waheed S, Alexander E, et al. Etiology of gastrointestinal bleeding in patients on dual antiplatelet therapy. J Dig Dis. 2018;19:66-73. doi: 10.1111/1751-2980.12575.10.1111/1751-2980.1257529314627Open DOISearch in Google Scholar

38. Nagata N, Niikura R, Aoki T, et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc. 2014;80:1124-1131. doi: 10.1016/j.gie.2014.06.039.10.1016/j.gie.2014.06.03925088922Open DOISearch in Google Scholar

39. Abdel Samie A, Theilmann L. Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do? J Gastrointestin Liver Dis. 2013;22:33-36.Search in Google Scholar

40. Carlin N, Asslo F, Sison R, Shaaban H, Baddoura W, Manji F, Depasquale J. Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding. J Emerg Trauma Shock. 2017;10:98-102. doi: 10.4103/JETS.JETS_110_15.10.4103/JETS.JETS_110_15556604228855770Search in Google Scholar

41. Oakland K, Desborough MJ, Murphy MF, Schachter M, Jairath V. Re-bleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Anti-platelets or Anti-coagulants. Clin Gastroenterol Hepatol. 2017;pii:S1542-3565(17)31528-8. doi: 10.1016/j.cgh.2017.12.032.10.1016/j.cgh.2017.12.03229277620Search in Google Scholar

42. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482.10.1056/NEJMoa070648217982182Open DOISearch in Google Scholar

43. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735-1749. doi: 10.1001/jama.2016.3775.10.1001/jama.2016.3775540857427022822Open DOISearch in Google Scholar

44. Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025-1034. doi: 10.1016/S0140-6736(17)30397-5.10.1016/S0140-6736(17)30397-5Open DOISearch in Google Scholar

45. Christ M, Popp S, Pohlmann H, et al. Implementation of high sensitivity cardiac troponin T measurement in the emergency department. Am J Med. 2010;123:1134-1142. doi: 10.1016/j.amjmed.2010.07.015.10.1016/j.amjmed.2010.07.015Open DOISearch in Google Scholar

46. Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J. 2002;23:1153-1176.10.1053/euhj.2002.3194Open DOISearch in Google Scholar

47. Bruno RR, Donner-Banzhoff N, Söllner W, et al. The Interdisciplinary Management of Acute Chest Pain. Dtsch Arztebl Int. 2015;112:768-779; quiz 780. doi: 10.3238/arztebl.2015.0768.10.3238/arztebl.2015.0768Open DOISearch in Google Scholar

48. Schüepp M, Ullmer E, Weinbacher M, et al. Chest pain early after percutaneous coronary intervention: incidence and relation to ECG changes, cardiac enzymes and follow-up events. J Invasive Cardiol. 2001;13:211-216.Search in Google Scholar

49. Kini AS, Lee P, Mitre CA, Duffy ME, Sharma SK. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol. 2003;41:33-38.10.1016/S0735-1097(03)80212-7Open DOISearch in Google Scholar

50. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897-907. doi: 10.1016/j.jacc.2010.07.028.10.1016/j.jacc.2010.07.02821109112Open DOISearch in Google Scholar

51. Marino BC, Nascimento GA, Rabelo W, et al. Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes. Arq Bras Cardiol. 2015;104:375-386. doi: 10.5935/abc.20140216.10.5935/abc.20140216449545225651344Open DOISearch in Google Scholar

52. Magalhaes MA, Minha S, Chen F, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 2014;7:768-776. doi: 10.1161/CIRCINTERVENTIONS.114.001341.10.1161/CIRCINTERVENTIONS.114.0013412546655125466551Open DOISearch in Google Scholar

53. Chang C, Chen Y, Ong E, et al. Chest pain after percutaneous coronary intervention in patients with stable angina. Clin Interv Aging. 2016;11:1123-1128. doi: 10.2147/CIA.S103605.10.2147/CIA.S103605499325527574412Open DOISearch in Google Scholar

54. Giustino G, Kirtane AJ, Baber U, et al. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016;117:1877-1883. doi: 10.1016/j.amjcard.2016.03.034.10.1016/j.amjcard.2016.03.03427131611Open DOISearch in Google Scholar

55. Casado Arroyo R, Polo-Tomas M, Roncales MP, et al. GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98:718-723. doi: 10.1136/heartjnl-2012-301632.10.1136/heartjnl-2012-301632Open DOISearch in Google Scholar

56. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108-1115. doi: 10.1161/CIRCULATIONAHA.110.973008.10.1161/CIRCULATIONAHA.110.973008Open DOISearch in Google Scholar

57. González-Pérez A, Sáez ME, Johansson S, Himmelmann A, García Rodríguez LA. Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses. BMC Cardiovasc Disord. 2016;16:164. doi: 10.1186/s12872-016-0348-6.10.1186/s12872-016-0348-6Open DOISearch in Google Scholar

58. Veitch AM. Endoscopy in Patients on Antiplatelet Agents and Anticoagulants. Curr Treat Options Gastroenterol. 2017;15:256-267. doi: 10.1007/s11938-017-0137-z.10.1007/s11938-017-0137-zOpen DOISearch in Google Scholar

59. Eisenberg MJ, Richard PR, Libersan D, et al. Safety of shortterm discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119:1634-1642. doi: 10.1161/CIRCULATIONAHA.108.813667.10.1161/CIRCULATIONAHA.108.813667Open DOISearch in Google Scholar

60. Sumayin Ngamdu K, El Mallah W, et al. One-Year Survival is Not Affected by Gastrointestinal Bleeding After Percutaneous Coronary Interventions. Am J Med Sci. 2017;353:381-386. doi: 10.1016/j.amjms.2017.01.017.10.1016/j.amjms.2017.01.017Open DOISearch in Google Scholar

61. Guo Y, Wei J. Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage. Exp Ther Med. 2016;12:1125-1129. doi: 10.3892/etm.2016.3378.10.3892/etm.2016.3378Open DOISearch in Google Scholar

62. Jensen BES, Hansen JM, Larsen KS, et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol Hepatol. 2017;29:1118-1125. doi: 10.1097/MEG.0000000000000934.10.1097/MEG.0000000000000934Open DOISearch in Google Scholar

63. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3:231-241. doi: 10.1016/S2468-1253(18)30037-2.10.1016/S2468-1253(18)30037-2Open DOISearch in Google Scholar

64. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, lowdose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834-839. doi: 10.1056/NEJM200009213431202.10.1056/NEJM20000921343120210995862Open DOISearch in Google Scholar

65. Fletcher EH, Johnston DE, Fisher CR, et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32:831-839. doi: 10.1111/j.1365-2036.2010.04415.x.10.1111/j.1365-2036.2010.04415.x20659284Open DOISearch in Google Scholar

66. Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World J Gastroenterol. 2014;20:9439-9450. doi: 10.1016/j.bpg.2012.01.006.10.1016/j.bpg.2012.01.00622542154Open DOISearch in Google Scholar

67. Leung Ki EL, Chan FK. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol. 2012;26:163-172. doi: 10.3748/wjg.v20.i28.9439.10.3748/wjg.v20.i28.9439411057525071338Open DOISearch in Google Scholar

68. Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111:705-710. doi: 10.1016/j.jfma.2011.11.028.10.1016/j.jfma.2011.11.02823265750Open DOISearch in Google Scholar

69. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Ann N Y Acad Sci. 2007;1108:594-602.10.1196/annals.1422.06217894024Search in Google Scholar

70. Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. J Dig Dis. 2012;13:342-349. doi: 10.1111/j.1751-2980.2012.00599.x.10.1111/j.1751-2980.2012.00599.x22713083Open DOISearch in Google Scholar

71. Liu J, Wang F, Shi S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants Helicobacter. 2015;20:176-183. doi: 10.1111/hel.12188.10.1111/hel.1218825382293Open DOISearch in Google Scholar

72. Kanbay M, Gur G, Yucel M, Yilmaz U, Muderrisoglu H. Helicobacter pylori seroprevalence in patients with coronary artery disease. Dig Dis Sci. 2005;50:2071-2074. doi: 10.1007/s10620-005-3009-7.10.1007/s10620-005-3009-716240217Open DOISearch in Google Scholar

73. Lee M, Baek H, Park JS, et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One. 2018;13:e0193646. doi: 10.1371/journal.pone.0193646.10.1371/journal.pone.0193646583417429499055Search in Google Scholar

74. Huang KW, Luo JC, Leu HB, et al. Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel. J Chin Med Assoc. 2013;76:9-14.10.1016/j.jcma.2012.09.00423331775Open DOISearch in Google Scholar